NetImpact Secures Option for New MDS200 License: Identify Infected Sheep and Goats, Protect Against Spread of Chronic Waste Dise
February 17 2004 - 2:06PM
PR Newswire (US)
NetImpact Secures Option for New MDS200 License: Identify Infected
Sheep and Goats, Protect Against Spread of Chronic Waste Disease
LAS VEGAS, Feb. 17 /PRNewswire-FirstCall/ -- NetImpact Holdings,
Inc. (OTC Pink Sheets: NTHD) announces the Company has secured an
option for a new exclusive license to further develop the MDS200
technology. Currently capable of testing humans for infectious
diseases, the new option allows a NetImpact team of MDS200
scientists to develop the technology to identify Chronic Wasting
disease in sheep and goats as well as Mad Cow Disease in cattle.
NetImpact expects the lab in a box to be ready to test for Mad Cow
disease and shortly thereafter for Chronic Wasting disease in 4-6
months. Chronic Wasting disease is similar to Mad Cow disease and
has been reported in animals roaming the U.S. One percent of white
tailed deer and fifteen percent of wild mule deer tested in captive
herds in Wisconsin and Colorado were found to be infected with
Chronic Wasting disease. The media and independent groups
monitoring the spread of the disease note that hunters are checking
whether animals they kill are testing positive. Hunters are
concerned that eating infected meat could develop
Creutzfeldt-Jakob, a neurological disorder that results in severe
cognitive impairment and possible death. The exact cause of the
spread of the disease from infected animal to normal animal is
unknown, but it may be transmittable through their saliva, urine,
feces, contaminated food and water. The MDS200 lab in a box
technology is being developed to specifically test cattle and is
expected to also identify the disease in sheep and goats, thus
protecting against its spread to humans. NetImpact is preparing to
apply to the National Institutes of Health and Department of
Defense for research and development monies to put these versions
of the lab in a box into use without delay. The Company is pursuing
partnerships with other firms and investment capital groups in the
U.S., Canada, England, Japan and Australia. About the MDS200 The
MDS200 lab in a box is a breakthrough technology for disease
detection. Currently used on solids, gases and fluids, it is
capable of automatic preparation and testing of difficult and dirty
samples containing cell, protein, nucleic acid and chemical
analytes. About the size of a small suitcase, the MDS200 is a
rugged portable laboratory designed for use in remote areas with
non-existent or scarce laboratory facilities and readily carried
from location to location.Test results are available in a matter of
hours, displayed on the unit's LED, and can be sent via satellite
or dial up connections to monitoring centers. Once sample has been
placed in the lab in a box the processing is spontaneous. Operating
an MDS200does not require a trained lab technician. About NetImpact
Holdings, Inc. NetImpact Holdings, Inc. is a technology-to-market
company focusing on the installation, restructuring and management
of global healthcare and medical delivery systems.
Throughacquisitions and extensive access to international/U.S.
distribution networks, NetImpact specializes in presenting
technology that will assist in the improvement of productivity,
applications development, and technology transfer in developing
countries. The Company's NetCare Division, Medical and Diagnostic
Devices Division, and Neurowave Division are moving their
technologies, products and services to an awaiting market. Safe
Harbor Statement The statements in this release that are not
historical facts are forward- looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. NetImpact Holdings, Inc. intends
that such forward-looking statements be subject to the safe harbors
created thereby. These forward-looking statements include
predictions, estimates and other statements that involve a number
of risks and uncertainties any, or all, of which could cause actual
results to differ materially from any future performance suggested
herein. While this outlook represents NetImpact Holdings, Inc.'s
current judgment on the future direction of the business, such
risks and uncertainties may individually, or mutually, impact the
matters herein described, including but not limited to product
acceptance, the economy, competition, governmental actions, results
of litigation, technological and/or other factors, which are
outside the control of NetImpact Holdings, Inc. as well as those
risks and uncertainties detailed in the Company's Security and
Exchange Commission filings. CONTACT Jerry Jennings Emerson Gerard
Associates 561-881-7318 DATASOURCE: NetImpact Holdings, Inc.
CONTACT: Jerry Jennings, Emerson Gerard Associates,
+1-561-881-7318, or , for NetImpact Holdings Web site:
http://www.netimpact.com/
Copyright